Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NeuroPace (NPCE) EBT (2020 - 2025)

Historic EBT for NeuroPace (NPCE) over the last 6 years, with Q3 2025 value amounting to -$3.6 million.

  • NeuroPace's EBT rose 3690.71% to -$3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.4 million, marking a year-over-year increase of 1854.87%. This contributed to the annual value of -$27.4 million for FY2024, which is 1591.86% up from last year.
  • According to the latest figures from Q3 2025, NeuroPace's EBT is -$3.6 million, which was up 3690.71% from -$8.2 million recorded in Q2 2025.
  • In the past 5 years, NeuroPace's EBT ranged from a high of -$3.6 million in Q3 2025 and a low of -$12.6 million during Q2 2022
  • For the 5-year period, NeuroPace's EBT averaged around -$8.2 million, with its median value being -$7.9 million (2021).
  • As far as peak fluctuations go, NeuroPace's EBT crashed by 11979.85% in 2021, and later soared by 4122.73% in 2023.
  • Over the past 5 years, NeuroPace's EBT (Quarter) stood at -$10.7 million in 2021, then decreased by 2.89% to -$11.0 million in 2022, then skyrocketed by 41.23% to -$6.5 million in 2023, then increased by 20.12% to -$5.2 million in 2024, then surged by 30.71% to -$3.6 million in 2025.
  • Its EBT stands at -$3.6 million for Q3 2025, versus -$8.2 million for Q2 2025 and -$6.5 million for Q1 2025.